On a filed basis, revenue rose 18.0% from KRW 2.22 billion in 2024 to KRW 2.62 billion in 2025. Over the same period the operating loss widened from KRW 14.6 billion to KRW 16.5 billion, and the operating margin moved from -661.0% to -632.8%.
In first-half 2026, R&D expenses were KRW 411 million, equal to 325.3% of revenue, and after government subsidies of KRW 398 million, the full amount was booked under selling and administrative expenses, according to a report on the half-year filing.
The cost base is far larger than revenue, so a higher top line has not narrowed losses. Net loss attributable to controlling shareholders widened from KRW 15.1 billion in 2024 to KRW 22.4 billion in 2025, and the net loss including non-controlling interests moved the same way.
Losses were recorded in both 2024 and 2025, and DailyHankook reported in April 2026 that the company had posted operating losses for four consecutive years. Operating cash flow went from -KRW 12.6 billion in 2024 to -KRW 15.1 billion in 2025.
Total equity at end-2025 was KRW 19.5 billion, with total liabilities of KRW 7.43 billion, and the debt-to-equity ratio moved from -119.3% in 2024 to 38.2% in 2025. The negative 2024 figure suggests equity was in negative territory that year.
Quarterly revenue went from KRW 763 million in the third quarter of 2025 to KRW 563 million in the fourth quarter (down 26.1% quarter on quarter), KRW 481 million in the first quarter of 2026 (down 14.5%), KRW 782 million in the second quarter (up 62.5%), and KRW 433 million in the third quarter (down 44.7%).
The company says its subscription base is supplemented by pharma imaging-analysis projects that can be recognized in the short term, as reported by BizWatch in August 2026, so quarterly swings in project revenue are large.
The operating loss was KRW 4.23 billion in the third quarter of 2025, KRW 4.36 billion in the fourth quarter, KRW 5.82 billion in the first quarter of 2026, KRW 5.23 billion in the second quarter, and KRW 5.69 billion in the third quarter, which is five consecutive quarters of losses on a filed basis.
Net loss attributable to controlling shareholders was KRW 6.39 billion in the third quarter of 2026, narrower than KRW 6.77 billion a year earlier, but the last four quarters total KRW 22.6 billion.